Infection Trends and dReiniger’s Response
Healthcare-associated infections (HAIs) cause significant morbidity and mortality worldwide, and result in billions of dollars in costs to healthcare systems and patients. In the United States, approximately 1.7 million nosocomial infections cause or contribute to 99,000 deaths each year. These infections are often difficult to treat especially if caused by antibiotic-resistant organisms such as MRSA, VRE and ESBL.
The most common route of transmission of nosocomial infection is by direct contact with healthcare workers or contaminated surfaces within a healthcare facility. Such surfaces include hospital textiles and healthcare worker clothing (scrubs, lab coats), which can serve as fomites, or sources of microbe colonization.
InvisiArmor Medical® US Patent 8,926,999
dReiniger US Patent 9,107,973
The 2016 U. S. Centers for Disease Control and Prevention (CDC) HAI Progress Report (http://www.cdc.gov/hai/surveillance/progress-report/index.html) indicates that “Despite progress, more action is needed at every level of public health and health care to eliminate infections that commonly threaten hospital patients…”, and that “On any given day, approximately one in 25 US patients has at least one infection contracted during the course of their hospital care, demonstrating the need for improved infection control in US healthcare facilities.”
dReiniger LLC believes that in order to reduce HAIs, professional guidance organizations and regulatory entities will be focusing on two key areas:
- Residual antimicrobial effect
- Compliance to best practices and standards
With these key requirements in mind, the company is developing and launching practical, eco-friendly products that provide residual antimicrobial protection and support compliance with infection prevention best practices.